For instance, they recommended anti-IgE therapy for allergic asthma, anti-IL-5 for eosinophilic asthma, and dupilumab as an option for eosinophilic or allergic asthma with frequent exacerbations, especially when maximal therapy has been reached (Cloutier et al., 2020). Here, IL5 is linked to allergic asthma.